Taşçı Tolga, Şükür Yavuz Emre, Özmen Batuhan, Atabekoğlu Cem Somer, Cengiz Sevim Dinçer, Koçbulut Evren, Berker Bülent, Sönmezer Murat
Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey.
Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey.
Eur J Obstet Gynecol Reprod Biol. 2014 May;176:50-4. doi: 10.1016/j.ejogrb.2014.02.034. Epub 2014 Feb 28.
To assess the effects of oral and transdermal hormone replacement therapies (HRT) on levels of important cardiovascular disease (CVD) markers, MCP-1 and homocyteine, in the early postmenopausal period.
Seventy-six healthy, early postmenopausal women were enrolled in the study. Patients were randomly assigned to receive oral or transdermal HRT for 6 months. The first group received continuous combined oral HRT containing 1mg 17β-estradiol and 0.5mg norethisterone acetate (n=39), and the second group received sequential transdermal HRT releasing 50μg/day estradiol alone given twice a week on days 1-14 and 50μg/day estradiol plus 0.25mg/day norethisterone acetate given twice a week on days 15-28 (n=37). Circulating levels of MCP-1 and homocysteine, along with other CVD markers, were assessed before and after treatment in all patients.
There were no significant differences between the baseline characteristics of the two groups. Baseline serum MCP-1 levels were similar between the oral and transdermal HRT groups (150.1±12.8 vs. 145.2±11.6pg/ml; P=.219). The mean MCP-1 levels did not change after 6 months of HRT in both oral (150.1±12.8 vs. 153.6±12.5pg/ml; P=.192) and transdermal HRT groups (145.2±11.6 vs. 146.1±15.1pg/ml; P=.419). Moreover, there was no significant difference between the groups in MCP-1 serum levels after 6 months of HRT. Similarly, no difference was found in serum homocyteine levels following 6 months of HRT.
Both oral continuous and sequential transdermal HRTs do not have significant effects on serum MCP-1 and homocyteine levels in women during the early postmenopausal period.
评估口服和经皮激素替代疗法（HRT）对绝经后早期重要心血管疾病（CVD）标志物单核细胞趋化蛋白-1（MCP-1）和同型半胱氨酸水平的影响。
76名健康的绝经后早期妇女纳入本研究。患者被随机分配接受口服或经皮HRT治疗6个月。第一组接受含1mg 17β-雌二醇和0.5mg醋酸炔诺酮的连续联合口服HRT（n = 39），第二组接受序贯经皮HRT，仅在第1 - 14天每周两次释放50μg/天雌二醇，在第15 - 28天每周两次释放50μg/天雌二醇加0.25mg/天醋酸炔诺酮（n = 37）。评估所有患者治疗前后MCP-1和同型半胱氨酸的循环水平以及其他CVD标志物。
两组的基线特征无显著差异。口服和经皮HRT组的基线血清MCP-1水平相似（150.1±12.8 vs. 145.2±11.6pg/ml；P = 0.219）。口服（150.1±12.8 vs. 153.6±12.5pg/ml；P = 0.192）和经皮HRT组（145.2±11.6 vs. 146.1±15.1pg/ml；P = 0.419）在HRT 6个月后平均MCP-1水平均未改变。此外，HRT 6个月后两组间MCP-1血清水平无显著差异。同样，HRT 6个月后血清同型半胱氨酸水平也无差异。
口服连续和序贯经皮HRT对绝经后早期女性血清MCP-1和同型半胱氨酸水平均无显著影响。
